Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dogwood Therapeutics, Inc.
| Form | Description | Links | |
|---|---|---|---|
| 13G/A | |||
| EFFECT | |||
| 10-Q | |||
| 8-K | |||
| S-3 | |||
| 4 | |||
| 13D/A | |||
| 13D/A | |||
| 8-K | |||
| 10-Q | |||
| 13G/A | |||
| 8-K | |||
| 8-K | |||
| 4 | |||
| 4 | |||
| 4 | |||
| 4 | |||
| 13G | |||
| 10-Q | |||
| 8-K | |||
| ARS | |||
| DEF 14A | |||
| PRE 14A | |||
| 8-K | |||
| 10-K |
1-25 of 332 filings
Recent SEC filings with analysis
- 10-QDogwood Therapeutics filed its Q3 2026 10-Q with a substantial-doubt going-concern disclosure: cash of $4.9 million plus $5 million raised in the October…
- 8-KDogwood Therapeutics reported a Q3 2026 net loss of $4.9 million ($0.14 per share), sharply narrower than the $15.7 million ($8.20 per share) loss a year ago,…
- S-3Dogwood Therapeutics filed an S-3 registering for resale 4,098,360 shares held by Sealbond Limited, its controlling stockholder, which bought the shares at…
- SCHEDULE 13D/AOn October 26, 2026, Sealbond Limited closed its previously announced private placement with Dogwood Therapeutics, purchasing 4,098,360 shares of common stock…
- SCHEDULE 13D/ADogwood Therapeutics disclosed in a Schedule 13D/A that controlling shareholder Sealbond Limited agreed on October 19, 2026 to purchase 4,098,360 shares at…
- 8-KDogwood Therapeutics signed a Subscription Agreement to sell 4,098,360 shares at $1.22 per share to Sealbond Limited, a subsidiary of its largest shareholder…